Themis is developing novel vaccines for high burden infectious diseases and oncology applications.
Total raised: $67.195534M
Investors 5
| Date | Name | Website |
| - | Weber Inve... | weberinves... |
| - | Adjuvant C... | adjuvantca... |
| - | Wellington... | wellington... |
| - | Hadean Ven... | hadeanvent... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 4
| Date | Series | Amount | Investors | Deal News |
| 18.09.2019 | Series D | $44.117971... | Hadean Ven... | fiercebiot... |
| 04.01.2018 | Series C | $12.066656... | - | wellington... |
| 05.09.2017 | - | $3.912597M | - | wellington... |
| 21.05.2011 | Series A | $7.09831M | - | finsmes.co... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 26.04.2021 | Vienna: Europe’s underestimated innovation hotspot | Austria ~ Company: With almost 200 000 highly-educated and multi-linguistic students, out of which... | therecursi... |
| 03.06.2020 | Joint against malaria: European Investment Bank, European Co... | Berlin, Luxembourg, 3 June 2020. Today, the European Investment Bank (EIB), the European Commission ... | realwire.c... |
| 26.05.2020 | Merck leaps into Covid-19 vaccine race, aiming to test two d... | Merck, one of the largest vaccine makers in the world, is entering the Covid-19 arena with an announ... | statnews.c... |
| 14.05.2020 | Themis collaborates with ABL Europe to manufacture its SARS-... | Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contr... | wellington... |
| 17.04.2020 | Themis announces Iain Dukes to join the company’s supervisor... | Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology co... | wellington... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images Latest update: May 26, 2020, at 5:10 pm E... | forbes.com... |
| 01.10.2019 | Themis and ZIKAVAX consortium announce initiation of Phase 1... | Themis announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccin... | wellington... |
| 18.09.2019 | Themis raises €40M to run phase 3 chikungunya vaccine trial... | Themis has raised €40 million ($44 million). The Merck-backed series D positions Themis to take its ... | fiercebiot... |
| 18.09.2019 | Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Se... | - | hadeanvent... |
| 18.09.2019 | Themis raises EUR 40 Million in Series D financing round bac... | Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 mil... | wellington... |
Show more